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Postmeal triglyceridemia and variability
of HbA1c and postmeal glycemia were
predictors of annual decline in estimated
glomerular filtration rate in type 2 diabetic
patients with different stages of
nephropathy
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Abstract
Background: This study examined associations of annual glycemic variability and postprandial dysmetabolism
with annual decline in estimated glomerular filtration rate (eGFR) in type 2 diabetic patients with different stages
of nephropathy.
Methods: Intrapersonal mean and coefficient of variation (CV) of HbA1c, fasting and postmeal concentrations of
plasma glucose (FPG and PMPG, respectively) and serum triglycerides (FTG and PMTG, respectively) during the first
12 months after enrollment were calculated in a cohort of 168 type 2 diabetic patients: 53 with optimal albumin/
creatinine ratio (ACR < 10 mg/g), 62 with high normal ACR (10–29 mg/g) and 53 with elevated ACR (≧30 mg/g).
Annual changes in eGFR were computed using 52 (median) creatinine measurements obtained over a median
follow-up of 6.0 years. Multivariate linear regressions assessed the independent correlates of changes in eGFR.
Results: Kidney function declined faster in patients with high normal and elevated ACR (−1.47 and −2.01 ml/min/
1.73 m2/year, respectively) compared to patients with optimal ACR (0.08 ml/min/1.73 m2/year, p < 0.05). In patients
with high normal ACR, age (standardized β、-0.30、p = 0.01), CV-HbA1c (standardized β、-0.66、p < 0.001) and
CV-PMPG (standardized β、-0.27、p = 0.01) was associated with annual eGFR decline independently of mean
HbA1c and PMPG, sex, BMI, waist circumference, diabetes duration and therapy, means and CVs of FPG and
systolic blood pressure, baseline eGFR, log ACR and uses of anti-hypertensive medications (R2 = 0.47). In patients with
elevated ACR, PMTG (standardized β、-0.408, p = 0.007) was associated with annual eGFR decline (R2 = 0.15).
Conclusions: Consistency of glycemic control and management of postprandial glycemia and lipidemia are important
to preserve kidney function in type 2 diabetic patients.
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Background
The incidence and prevalence of chronic kidney disease
are increasing [1], and it has been recognized as a med-
ical, social, and economic problem worldwide. A mild
decline of kidney function increases the risk of cardio-
vascular disease in the general population [2]. Therefore,
the early detection and aggressive modification of risk
factors for the decline of kidney function are important.
Aging, hypertension, and diabetes mellitus are the most
common risk factors for the development of chronic
kidney disease [3, 4]. In addition to hypertension and
diabetes, dyslipidemia has an important role in the
progression of kidney disease in patients with diabetes
[5]. Longitudinal studies have found an association
between fasting serum triglycerides (FTG) and the de-
velopment of chronic renal insufficiency [6–9]. How-
ever, we are not aware of report that examined
associations of postmeal TG (PMTG) with changes in
kidney function despite the fact that the vasculature
is commonly exposed to prolonged and exaggerated
postprandial triglyceridemia, especially in type 2 dia-
betic patients [10].
There is emerging interest to examine the influence of
glycemic and BP variance in diabetic vascular complica-
tions [11, 12]. Recently, we have shown direct associ-
ation of HbA1c variability and albuminuria with kidney
function decline in type 2 diabetic patients [13]. We,
therefore, asked the question whether glycemic variabil-
ity, fasting and postmeal TG might directly associated
with annual decline in estimated glomerular filtration
rate (eGFR) in patients with type 2 diabetes with differ-
ent stages of nephropathy.
Methods
The setting for this observational study was the same as
previously reported [13]. Study protocol was consistent
with the Japanese Government’s Ethical Guidelines Re-
garding Epidemiological Studies in accordance with the
Declaration of Helsinki. Patients with hepatitis B surface
antigen or antibodies against hepatitis C virus were ex-
cluded. Those who had aspartate aminotransferase and
alanine aminotransferase of 100 U/L or greater, serum
creatinine≧2.0 mg/dl were excluded as well. We exam-
ined a cohort of 168 patients with type 2 diabetes in
whom 153 patients (91%) had 12 monthly visits with
blood samplings [13]. They had been regularly attending
the clinic in 2004 and 2005. They were enrolled in the
study at the first visit in 2005 and followed up for the
subsequent at least 24 months through December 31,
2012 to assess kidney function with a median follow-up
of 6.0 years (interquartile range; 4.1–6.5 years). In the
153 patients, blood was withdrawn on 2 occasions; at
2 h after breakfast taken at home and after an overnight
fasting. This was done every other month. In the
remaining 15 patients, blood was obtained after an over-
night fasting.
For each subject on each monthly visit, waist cir-
cumference, weight and BP were measured by regis-
tered nurses. Plasma glucose (PG) was determined by
the glucose oxidase method using an autoanalyzer
(Glucoroder MAX, A&T, Yokohama, Japan). Serum
lipids and lipoproteins, creatinine, hepatic enzymes,
uric acid and other blood tests were measured by
standard methods using an autoanalyzer (H7600,
Hitachi, Tokyo, Japan). HbA1C values were deter-
mined by high performance liquid chromatography
(HLC723-G7, Tosoh, Tokyo, Japan). Urinary albumin
was measured once during the first 3–4 months after
enrollment in random urine samples using a turbidi-
metric immunoassay and expressed as albumin /cre-
atinine ratio (ACR). Serum and urinary creatinine
were measured enzymatically and estimated glomeru-
lar filtration rate (eGFR) was determined using the
equation recommended by the Japanese Society for
Nephrology [14].
Microalbuminuria was defined as ACR between 30
and 299 mg/g [15]. The recommended normal range
was further subdivided into high normal ACR (10–
29 mg/g) and optimal ACR (<10 mg/g) [16]. Because
relatively few participants (n = 6) had macroalbumi-
nuria (ACR ≥300 mg/g), these participants were
grouped with those who had microalbuminuria and
were termed as elevated ACR.
Intrapersonal mean and coefficient of variation (CV)
of HbA1c, fasting and postmeal plasma glucose (FPG
and PMPG, respectively) and serum triglycerides (FTG
and PMTG, respectively) taken during the first
12 months after enrollment were calculated; 153 patients
(91%) had 12 measurements of HbA1c and systolic BP,
and 6 measurements of FPG, PMPG, FTG and PMTG,
respectively. Linear regression was used to estimate
changes in eGFR using a median of 52 creatinine mea-
surements (interquartile range; 31–60) over 6.0 years of
follow-up in each patient.
Data were presented as mean ± SE unless otherwise
stated. Differences between 2 groups were analyzed by t
test and frequencies of conditions by Chi-square tests.
Differences among 3 groups were analyzed using analysis
of variance and then Bonferroni’s multiple comparison
procedure was done. Correlations of annual eGFR de-
cline were evaluated by Pearson correlation analysis.
Multiple linear regression analyses were performed to
further identify the most significant variables contribut-
ing to annual eGFR decline. Potential confounders were
forced into the model and standardized β coefficients
were calculated. A two-tailed P < 0.05 was considered
statistically significant. All calculations were performed
with SPSS system 15.0 (SPSS Inc., Chicago, IL).
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Results
As previously reported [13], patients had relatively
good glycemic, lipid and BP control. Baseline means
of eGFR were means of 2–4 measurements during
the first 3–4 months after enrollment, and averaged
76 ± 16 ml/min/1.73 m2. Changes in eGFR were
linear and averaged −1.05 ± 3.39 ml/min/1.73 m2 per
year. At baseline, 27 (16.0%) of 168 patients had
eGFR < 60 ml/min/1.73 m2 and 53, 62 and 53
patients had optimal, high normal and elevated ACR
(microalbuminuria 47, macroalbuminuria 6),
respectively.
Patients with elevated compared to optimal ACR were
older, had higher mean HbA1c, FPG and PMPG
(Table 1). Patients with elevated ACR had higher FTG
and systolic BP and lower HDL cholesterol. In patients
with high normal and elevated ACR eGFR decreased
whereas eGFR did not change in patients with optimal
ACR. There was no difference in baseline eGFR among
3 groups and other variables.
In patients with high normal ACR, annual eGFR
change was inversely associated with CV-HbA1c,
CV-FPG and CV-PMPG but not with means of the 3
glycemic variables (Table 2). However, annual eGFR
decline did not show significant associations with
age, sex, duration of diabetes, baseline eGFR, treat-
ment for diabetes, lipids and BP variables. Multiple
linear regression analysis revealed that age (standard-
ized β、-0.30、p = 0.01), CV-HbA1c (standardized
β、-0.66、p < 0.001) (Fig. 1a) and CV-PMPG
(standardized β、-0.27、p = 0.01) (Fig. 1b) was asso-
ciated with annual eGFR decline independently of
mean HbA1c and PMPG, sex, BMI, waist circumfer-
ence, diabetes duration and therapy, means and CVs
of FPG and systolic blood pressure, baseline eGFR,
log ACR and uses of anti-hypertensive medications
(R2 = 0.47).
In patients with elevated ACR, annual eGFR de-
cline was inversely associated with CV-HbA1c,
PMTG and urinary ACR and positively with treat-
ment of hypertension and systolic BP (Table 2).
However, annual eGFR decline did not show signifi-
cant association with any other variables. Multiple
linear regression analysis revealed that PMTG (stan-
dardized β、-0.408, p = 0.007) (Fig. 1c) was associated
with annual eGFR decline independently of CV-
HbA1c, age, sex, BMI, waist circumference, duration
and treatment of diabetes, means and CVs of HbA1c,
FPG and PMPG, FTG, baseline eGFR, log ACR and
uses of anti-hypertensive and lipid-lowering medica-
tions (R2 = 0.15).
There was no significant association between eGFR
changes and any variables studied in patients with opti-
mal ACR (Table 2).
Discussion
The current study is the first to demonstrate direct asso-
ciations of annual variation in HbA1c and PMPG with
annual decline in eGFR in patients with type 2 diabetes
and high normal ACR. In addition, the current study is
Table 1 Baseline features of type 2 diabetic patients with
optimal, high normal and elevated urinary albumin/creatinine
ratio (ACR)







(n = 53) (n = 62) (n = 53)
Male sex (n, %) 32,61.5 26,42.6 31,58.5
Smokers (n, %) 15,28.8 22,36.1 20,37.7
Age (years) 59.4 ± 1.4a 63.0 ± 1.2a,b 64.2 ± 1.4b
BMI (kg/m2) 23.9 ± 0.4 23.9 ± 0.4 25.0 ± 0.6
Waist circumference (cm) 85.3 ± 1.1 86.6 ± 1.0 89.1 ± 1.9








HbA1c (%) 6.8 ± 0.1a 7.0 ± 0.1a,b 7.3 ± 0.1b
Fasting PG (mg/dl) 120 ± 3a 125 ± 3a,b 130 ± 3b
Post-breakfast PG (mg/dl) 137 ± 6a 155 ± 6b 169 ± 8b
CV-HbA1c (%) 6.5 ± 1.1 6.5 ± 0.7 8.0 ± 0.8
CV-Fasting PG (%) 12.0 ± 1.0 15.4 ± 1.3 14.4 ± 1.2
CV-Post-breakfast PG (%) 19.7 ± 1.2 22.9 ± 1.6 23.0 ± 1.9
Total cholesterol (mg/dl) 191 ± 3 188 ± 3 186 ± 3
LDL cholesterol (mg/dl) 113 ± 2 111 ± 3 110 ± 4
HDL cholesterol (mg/dl) 59 ± 2a 55 ± 2a,b 53 ± 2b
Fasting TG (mg/dl) 102 ± 6a 112 ± 5a,b 130 ± 9b
Post-breakfast TG (mg/dl) 134 ± 9 146 ± 8 159 ± 10
Serum creatinine (mg/dl) 0.77 ± 0.02 0.72 ± 0.02 0.78 ± 0.03
eGFR (ml/min/1.73 m2) 75.1 ± 1.8 77.0 ± 2.0 75.3 ± 2.7
⊿eGFR (ml/min/1.73 m2/
year)
0.08 ± 0.33a −1.47 ± 0.43b −2.01 ± 0.40b
Uric acid (mg/dl) 5.23 ± 0.16 4.92 ± 0.17 5.50 ± 0.20
Systolic BP (mmHg) 126 ± 2a 127 ± 1a 132 ± 2b
CV-Systolic BP (%) 7.7 ± 0.3 8.1 ± 0.3 8.3 ± 0.3
Diastolic BP (mmHg) 73 ± 1 72 ± 1 72 ± 1
Urinary ACR (mg/g) 6.4 ± 0.4a 17.2 ± 0.6a 236 ± 75b
log ACR 0.7 ± 0.0a 1.2 ± 0.0b 1.9 ± 0.1c
Mean ± SE or %. OHA oral hypoglycemic agents, CCB calcium channel blockers,
RASi renin-angiotensin system inhibitors, PG plasma glucose, CV coefficient of
variation, eGFR estimated glomerular filtration rate, ⊿eGFR annual changes in
eGFR, BP blood pressure, ACR albumin/creatinine ratio
Means not sharing common alphabetical letters are significantly different each
other at p < 0.05 or less. Means without a letter indicate no statistical
significance among 3 groups.
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also the first to demonstrate direct associations of
PMTG with annual decline in kidney function in type 2
diabetic patients with elevated ACR. These associations
were independent of mean HbA1c and PMPG, FTG and
known predictors of GFR decline [17]. The current find-
ing that kidney function decline was faster in patients
with high normal compared to optimal ACR has con-
firmed previous studies that urinary albumin, even in
the microalbuminuric range, is a predictor of renal func-
tion impairment [17–20].
As mentioned earlier, longitudinal studies have found
an association between FTG and renal replacement
therapy in type 2 diabetic patients [6], GFR decline in
patients with chronic glomerulonephritis [7], a rise in
serum creatinine of 0.4 mg/dL or greater in the general
population [8] and development of renal impairment in
type2 diabetic patients [9]. In the UK prospective
Diabetes Study [21], high levels of FTG were a inde-
pendent risk factor of micro- and macro-albuminuria.
The present study is the first to demonstrate that PMTG
but not FTG was associated with annual GFR decline in
type 2 diabetic patients with nephropathy (elevated
ACR). CV of HbA1c, which showed strong association
in univariate analysis, did not emerge as an independent
predictor of annual eGFR decline in patients with ele-
vated ACR, although it was independently associated
with annual eGFR decline in the entire 168 patients as
recently reported [13].
Recent meta-analyses [11, 22] indicated that higher
HbA1C variability was independently associated with
higher risk of renal disease in both type 1 and 2 diabetes
patients. Our previous study was the first to show a dir-
ect association between annual HbA1c variability and
kidney function decline and demonstrated stronger asso-
ciation in type 2 diabetic patients with elevated ACR
than in patients with normoalbuminuria [13]. In the
present study, patients with normoalbuminuria were di-
vided into 2 groups: those with optimal and high normal
ACR and 2 groups were analyzed separately. Annual
eGFR decline was independently associated with CV of
HbA1c in patients with high normal ACR but not in
patients with optimal and elevated ACR.
In a recent systematic review [23], only 2 studies
assessed the association of postprandial glucose with ret-
inopathy [24, 25] but no report with diabetic kidney dis-
ease. The current study is the first to demonstrate direct
associations of annual variation in PMPG but not mean
PMPG with annual decline in eGFR in type 2 diabetic
patients with high normal ACR. We are aware of only 1
prospective study [26] assessing the relationship between
variation in FPG and risk of kidney disease in type 2
diabetic patients. Lin et al. [26] reported that annual
variation in HbA1c and FPG was independently asso-
ciated with risk of diabetic nephropathy (eGFR <
60 mL/min/1.73 m2). Among 4399 patients with type
2 diabetes in the intensive group of the ADVANCE
trial [27], SD of FPG and HbA1c independently
predicted future combined microvascular events
(nephropathy or retinopathy).
Several mechanisms including oxidative stress and in-
flammation may be involved in the association between
glycemic variability and outcomes as recently discussed
in detail [11]. Current findings of independent associa-
tions of PMTG and CV-PMPG with annual decline in
kidney function in type 2 diabetic patients may be in line
with the observation of an independent effect of
Table 2 Correlation coefficients of annual changes in estimated
glomerular filtration rates in type 2 diabetic patients with








Male sex (n, %) −0.163 −0.008 0.207
Smokers (n, %) −0.182 −0.226 −0.022
Age (years) −0.115 −0.028 0.175
BMI (kg/m2) −0.232 0.094 −0.110
Waist circumference (cm) −0.277 −0.030 −0.099
Duration of diabetes (years) −0.242 −0.170 0.081
Treatment of




HbA1c (%) −0.094 −0.097 0.045
Fasting PG (mg/dl) −0.096 −0.148 0.113
Post-breakfast PG (mg/dl) −0.083 −0.080 0.086
CV-HbA1c (%) 0.164 −0.509*** −0.400**
CV-Fasting PG (%) −0.050 −0.424** −0.233
CV-Post-breakfast PG (%) −0.067 −0.330* −0.056
Total cholesterol (mg/dl) 0.103 −0.067 0.114
LDL cholesterol (mg/dl) 0.000 −0.094 0.083
HDL cholesterol (mg/dl) 0.130 −0.009 0.170
Fasting TG (mg/dl) −0.091 0.013 −0.257
Post-breakfast TG (mg/dl) −0.054 0.014 −0.343*
Serum creatinine (mg/dl) 0.029 0.006 −0.132
eGFR (ml/min/1.73 m2) 0.013 −0.128 −0.034
⊿eGFR (ml/min/1.73 m2/year) 1.000 1.000 1.000
Uric acid (mg/dl) −0.040 −0.082 −0.080
Systolic BP (mmHg) −0.164 −0.109 0.302*
CV-Systolic BP (%) −0.107 −0.156 0.064
Diastolic BP (mmHg) −0.085 −0.002 0.146
Urinary ACR (mg/g) −0.012 −0.157 −0.281*
log ACR −0.077 −0.169 −0.034
Abbreviations are the same as in Table 1 *: p < 0.05, **: p < 0.01, ***: p < 0.001
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postprandial hypertriglyceridemia and hyperglycemia on
endothelial dysfunction and oxidative stress generation
in both diabetic and normal subjects [28].
Type 2 diabetic patients with high normal and elevated
ACR in the present study had annual eGFR decline
(−1.47 and −2.01 ml/min/1.73 m2 per year, respectively)
which was comparable to non-diabetic Japanese
patients with early-stage chronic kidney disease
(eGFR > 60 ml/min/1.73 m2) (−1.64 ml/min/1.73 m2
per year) [29]. Further, annual eGFR decline of our
patients was slower than the rate found in Japanese
type 2 diabetic patients without clinical albuminuria
(−2.94 ml/min/1.73 m2 per year) [30] despite compar-
able baseline eGFR. These findings may be due in
part to the fact that our patients had better glycemic
(mean HbA1c; 7.0–7.3 vs. 8.4%) and BP (127–132 vs.
135 mmHg) control. Slower eGFR decline associated
with better diabetic control in our patients may be
related to failure to detect association between mean
HbA1c and annual eGFR decline in the present study.
The strength of the current study is that we used 12-
month period when mean HbA1c and HbA1c variability
were calculated from 12 measurements in 91% partici-
pants. Postmeal TG were measured after breakfast eaten
at home: in real-life conditions. In addition, serum cre-
atinine and hence eGFR during follow-up period were
measured much more frequently than in previous stud-
ies as mentioned elsewhere [13]. This could contribute
to the reliability of changes in kidney function. Such a
testing frequency is routine in clinical settings in Japan.
However, frequent measures of HbA1c may artificially
inflate precision and decrease standard deviation, which
may impact the results. Finally, BP control and variabil-
ity and postprandial TG also have been taken into
accounted. Major limitations are that study participants
were small in number and from a single clinic in Japan.
However, the characteristics of our study participants
are similar to those reported in a previous large-scale
study in Japan [31]. Another limitation was that urinary
ACR was measured once in a random urine sample.
Since the albumin excretion variability is too high, classi-
fication of patients according to single measurement of
ACR may be unreliable.
Conclusions
The current study has demonstrated that predictors of
annual decline in kidney function differed in type 2 dia-
betic patients with different stages of nephropathy.
These findings suggest that more attention should be
paid by clinicians in diabetes control, avoiding excessive
oscillations in blood glucose levels in type 2 diabetic
patients with high normal ACR. In patients with
ACR≧30 mg/g, management of postmeal TG may be im-
portant because normotriglyceridemic patients with type
2 diabetes and microalbuminuria have an almost 3-fold
higher postprandial triglyceridemia than patients without
microalbuminuria after ingestion of a mixed test meal
[32]. Further studies are needed to confirm the
association in other ethnic groups with more patients.
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